Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Ciphergen Implicates Four Proteins in Early-Stage Ovarian Cancer

  • Ciphergen Biosystems report that it has discovered four proteins that may be potential diagnostic markers for early-stage ovarian cancer. Along with collaborators, the researchers say that these four proteins in urine separate women with early cancer from healthy individuals with a sensitivity of 56% and a specificity of 95%.

    To elucidate these findings, Ciphergen employed protein expression profiling methods to analyze urine samples from 400 women, including 288 women with epithelial ovarian cancer, 52 with early-stage disease, and 176 with late-stage disease, 74 women with benign ovarian disease, and 98 normal, healthy controls.

    "By demonstrating that these findings are reproducible, Ciphergen hopes to advance these markers beyond the clinical validation process and into clinical trials," says Eric T. Fung, M.D., Ph.D., CSO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »